So I think that the HRD negative face several challenges. First is the testing because that is not completely predictive of the benefit of PARP inhibitors. Second is the prognosis. Those patients do have a very worse prognosis, 90% relapse in three years. Third is the predictive value of being HRD. They are less responsive to platinum-based therapy, as well as less responsive to PARP inhibitor...
So I think that the HRD negative face several challenges. First is the testing because that is not completely predictive of the benefit of PARP inhibitors. Second is the prognosis. Those patients do have a very worse prognosis, 90% relapse in three years. Third is the predictive value of being HRD. They are less responsive to platinum-based therapy, as well as less responsive to PARP inhibitor. So we are facing really a new group of patients with high-unmet needs. What is the future for this patient? I think that targeting BRCA1 proteins and pathways will be one of the most strongest research strategies, as well as the incorporation of ADCs for these patients in the setting of probably even the maintenance in Farletuzumab on top of Bevacizumab could be one of the strategies that we will see very soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
